Exposure to ozone pollution is associated with increased CVS-related hospitalizations

Published Date: 13 Mar 2023

Researchers have found in a new study that exposure to ozone pollution can increase the number of hospitalizations associated with heart disease. Also...

Read Full News

Latest News

No New Safety Signals Over 3 Years in HS With Bimekizumab: Amit Garg, MD Amit Garg, MD

Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

RLS-1496 Cream Reduces Actinic Keratosis Lesions Mary Spellman, MD

Topical GPX4 inhibitor RLS-1496 1% reduced AK lesion counts by 43.5% vs 11.3% with untreated control at Day 57, with no application site reactions.

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

Why Dermatologists Should Stay Involved in Advanced Cutaneous SCC Shannon C. Trotter, DO

Shannon C. Trotter, DO, FAOCD, discusses immunotherapy in advanced cutaneous squamous cell carcinoma and why dermatologists should stay involved.

Todays Updates

Episode 178: Evolving Approaches to Epilepsy Clinical Trial Design Isabella Ciccone, MPH, M. Scott Perry, MD, Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]

Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials Isabella Ciccone, MPH

The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.

Todays Updates

Episode 178: Evolving Approaches to Epilepsy Clinical Trial Design Isabella Ciccone, MPH, M. Scott Perry, MD, Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]

Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials Isabella Ciccone, MPH

The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.

Latest News

Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

Topical GPX4 inhibitor RLS-1496 1% reduced AK lesion counts by 43.5% vs 11.3% with untreated control at Day 57, with no application site reactions.

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

Shannon C. Trotter, DO, FAOCD, discusses immunotherapy in advanced cutaneous squamous cell carcinoma and why dermatologists should stay involved.

News All Time

Fall Clinical 2026 Second Half Recap: Acne, Skin Cancer, and More

Fall Clinical 2026 Second Half Recap: Acne, Skin Cancer, and More

Advances in Treating High-Impact Psoriasis from EADV 2026 Christopher G. Bunick, MD, PhD

Chris Bunick, MD, PhD, discusses 52-week UnlIMMited data showing risankizumab sustained clearance, itch relief, and quality-of-life gains.

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Nemolizumab Safety, Real-World Use in AD, With Matthias Augustin, MD Matthias Augustin, MD

An ARCADIA investigator says patients in practice match the 3-year trial results and outlines next steps for IL-31 research.

No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH Christina Chambers, PhD, MPH

Chambers discusses final results from a 7-year dupilumab pregnancy registry showing no evidence of increased risk for major birth defects or other outcomes.

Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD Iltefat Hamzavi, MD

Iltefat H. Hamzavi, MD, discusses phase 3 Tranquillo data showing higher facial and total body repigmentation with ritlecitinib in vitiligo.

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Nemolizumab Sustains AD Response at 3 Years, With Matthias Augustin, MD Matthias Augustin, MD

Up to 91% of patients reached EASI-75 at week 152 in the ARCADIA LTE, with consistent safety and gains in itch and quality of life.

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Navigating Corticosteroid Stewardship in Dermatology, With Kristina Derrick, MD Kristina Derrick, MD

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Recommended News For You

Unified Neuro/Psych Residency Program: New Proposal.

Sickle Cell Disease Drug Pulled From Global Markets

De-Intensified Therapy Misses Mark in HPV-Positive Oropharyngeal Cancer

Preferred and Actual Location of Death Often Don't Match for Young Cancer Patients

TRK Inhibitor Active in Treatment-Refractory Glioblastoma

Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.

The Higher the Disability Burden From Disease, the Higher the Suicide Risk

Recommended Articles For You

Advanced Pathways in Oncology for Better Care 

The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting  

Deep Learning Fluorescence Imaging for Oral Cancer Surgery: In Silico Depth Quantification 

Platelet Production Dynamics During Early Life 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Efanesoctocog Alfa Prevented Bleeding in Kids With Severe Hemophilia A

2.

Snus Linked to Gingival Damage, Raising Safety Questions

3.

Papillary thyroid cancer: New markers offer hope for tailored treatment

4.

NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

5.

"Unusual" Cancers Following Pandemic; Triumph in TNBC; Clinical Trial Interrupted by Shortage.

1.

Emerging Therapies Using Targeted Antibody–Drug Conjugates Against Previously Difficult Tumor Targets

2.

Prevention Through Cancer Survivorship: Strategies to Reduce Long-Term Functional Decline

3.

Understanding Neutrophilia: Causes, Symptoms, and Treatment Options

4.

Hematopoietic Lineage Commitment Through Single-Cell Functional Genomics: Insights, Mechanisms, and Clinical Implications

5.

Immune-Engaging Antibody Platforms: Mechanisms, Clinical Applications, and Emerging Therapeutics

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Navigating the Complexities of Ph Negative ALL - Part X

2.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

3.

Best Practices in Hematology

4.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV

5.

Understanding Common Causes of Abnormal Blood Counts

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot